194 related articles for article (PubMed ID: 35905710)
1. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
[TBL] [Abstract][Full Text] [Related]
2.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
3. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
[TBL] [Abstract][Full Text] [Related]
5. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
6. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
7. Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
Chilamakuri R; Agarwal S
Curr Oncol; 2022 Sep; 29(9):6508-6522. PubMed ID: 36135081
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
See WL; Tan IL; Mukherjee J; Nicolaides T; Pieper RO
Cancer Res; 2012 Jul; 72(13):3350-9. PubMed ID: 22573716
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling.
Sandoval JA; Eppstein AC; Hoelz DJ; Klein PJ; Linebarger JH; Turner KE; Rescorla FJ; Hickey RJ; Malkas LH; Schmidt CM
J Surg Res; 2006 Jul; 134(1):61-7. PubMed ID: 16650873
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA SNHG16 regulates cell behaviors through miR-542-3p/HNF4α axis via RAS/RAF/MEK/ERK signaling pathway in pediatric neuroblastoma cells.
Deng D; Yang S; Wang X
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32412051
[TBL] [Abstract][Full Text] [Related]
13. BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
Uçkun E; Siaw JT; Guan J; Anthonydhason V; Fuchs J; Wolfstetter G; Hallberg B; Palmer RH
J Mol Biol; 2021 Sep; 433(19):167158. PubMed ID: 34273398
[TBL] [Abstract][Full Text] [Related]
14. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
Fedele C; Ran H; Diskin B; Wei W; Jen J; Geer MJ; Araki K; Ozerdem U; Simeone DM; Miller G; Neel BG; Tang KH
Cancer Discov; 2018 Oct; 8(10):1237-1249. PubMed ID: 30045908
[TBL] [Abstract][Full Text] [Related]
15. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.
Malone CF; Kim M; Alexe G; Engel K; Forman AB; Robichaud A; Conway AS; Goodale A; Meyer A; Khalid D; Thayakumar A; Hatcher JM; Gray NS; Piccioni F; Stegmaier K
Cancer Res; 2023 Jan; 83(2):285-300. PubMed ID: 36398965
[TBL] [Abstract][Full Text] [Related]
18. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
Pfeiffer A; Franciosa G; Locard-Paulet M; Piga I; Reckzeh K; Vemulapalli V; Blacklow SC; Theilgaard-Mönch K; Jensen LJ; Olsen JV
Cancer Res; 2022 Jun; 82(11):2141-2155. PubMed ID: 35311954
[TBL] [Abstract][Full Text] [Related]
20. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
Whittaker SR; Theurillat JP; Van Allen E; Wagle N; Hsiao J; Cowley GS; Schadendorf D; Root DE; Garraway LA
Cancer Discov; 2013 Mar; 3(3):350-62. PubMed ID: 23288408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]